The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -97,172 |
| Depreciation and amortization | 168 |
| Non-cash lease expense | 497 |
| Stock-based compensation | 8,863 |
| Change in fair value of tranche rights | 0 |
| Fees expensed as part of january 2024 financing | 0 |
| Foreign currency loss | 0 |
| Other current assets and prepaid expenses | 3,161 |
| Accounts payable | 1,237 |
| Operating lease liabilities | -506 |
| Other liabilities | -209 |
| Accrued expenses | 4,477 |
| Net cash used in operating activities | -85,806 |
| Purchases of property and equipment | 161 |
| Net cash used in investing activities | -161 |
| Proceeds from january 2024 financing, net of issuance costs-January2024PIPETransaction | 0 |
| Proceeds from public offering of common stock through at the market offering, net of issuance costs | 0 |
| Proceeds from shares issued in connection with the company's employee stock purchase plan | 182 |
| Proceeds from january 2024 financing, net of issuance costs-May2025PIPETransaction | 60,661 |
| Proceeds from january 2024 financing, net of issuance costs-April2025PIPETransaction | 4,734 |
| Net cash provided by financing activities | 65,577 |
| Effect of exchange rate changes on cash and cash equivalents | 205 |
| Net change in cash and cash equivalents | -20,185 |
| Cash and cash equivalents, beginning of year | 35,668 |
| Cash and cash equivalents, end of year | 15,483 |
IMMUNIC, INC. (IMUX)
IMMUNIC, INC. (IMUX)